中国药理学通报2025，Vol.41Issue(12)：2212-2218,7.DOI:10.12360/CPB202507039
靶向Tau蛋白的抗阿尔茨海默病药物研究进展
Anti-Alzheimer's disease drug development target on Tau
摘要
Abstract
Alzheimer's disease(AD)is the most common cause of cognitive impairment in the elderly,and the formation of intracellular neurofibrillary tangles(NFT)due to the hyperphos-phorylation of Tau is one of its important pathological features.Compared to β-amyloid,the hyperphosphorylation of Tau and the resulting NFT are more closely related to the decline in cognitive ability.This review focuses on anti-AD drugs targeting Tau,em-phasizing the latest progress in inhibiting the hyperphosphoryla-tion of Tau protein,alleviating the aggregation of Tau protein,re-ducing the cytoskeletal damage caused by the hyperphosphoryla-tion of Tau protein by stabilizing microtubules,and immunothera-py,in the hope of providing new insights into drug research for AD and related cognitive disorders associated with Tau protein.关键词
阿尔茨海默病/Tau蛋白/过度磷酸化/蛋白质聚集/免疫疗法/人工智能Key words
Alzheimer's disease/Tau protein/hyperphospho-rylation/protein aggregation/immunotherapy/artificial intelli-gence分类
医药卫生引用本文复制引用
张天怡,屈山河,王雯翡,张钊,楚世峰..靶向Tau蛋白的抗阿尔茨海默病药物研究进展[J].中国药理学通报,2025,41(12):2212-2218,7.基金项目
国家自然科学基金资助项目(No U2202214) （No U2202214）
国家重点研发计划(No 2022YFC3500301) （No 2022YFC3500301）
